AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03550014 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low Back+Hip
Description: The physical therapy interventions are commonly performed in and may include stretching, strengthening, hands-on techniques, etc. The interventions will be directed at the lower back and the hips. Standard plan of care delivered to participants with low back pain and concurrent hip impairments within scope of licensure.
Study NCT01033097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNK333 5 mg
Description: 5 mg oral
Study NCT01033097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to 5 mg
Description: 5 mg placebo oral
Study NCT01033097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNK333 25 mg
Description: 25 mg oral
Study NCT01033097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to 25 mg
Description: 25 mg placebo oral
Study NCT01033097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNK333 100 mg
Description: 100 mg oral
Study NCT01033097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to 100 mg
Description: 100 mg placebo oral
Study NCT01033097 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone 4 mg
Description: 4 mg oral
Study NCT01033097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNK333 1mg
Description: 1 mg oral
Study NCT01033097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to 1mg
Description: 1 mg placebo oral
Study NCT01339156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P3914
Description: Part A:~The subjects will be fasted overnight for at least 10 hrs.The drug will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. Each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product will be administered orally to each subject with 240 mL of water.~Part C:~Dosing will take place on Day 1 of each study period. Each subject will receive a single oral dose.~For administration of P3914 tablets subjects will be required to fast for 10 hrs prior to dosing.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery).
Study NCT01339156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A:~The subjects will be fasted overnight for at least 10 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. It is planned that each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject with 240 mL of water.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery).
Study NCT01374971 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Certolizumab Pegol (CZP)
Description: CZP is an anti-TNF, humanized antibody Fab' fragment/polyethylene glycol(PEG)conjugate. CZP liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks.
Study NCT01374971 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopic synovial tissue biopsy
Description: Subjects will undergo arthroscopy Pre and Post Treatment. The arthroscopy will be performed on a clinically inflamed joint. A single arthroscopy procedure using a small bore arthroscope will be conducted to obtain synovial tissue in each joint in all subjects. Local anesthesia will be used only. Two small incisions will be made to accommodate the arthroscope and other instruments. Synovial biopsies will be obtained using a motorized shaver.
Study NCT03468387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary realignment
Description: Endoscopic realignment of rupture urethra over a urethral catheter
Study NCT01388816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DRL-17822 or placebo
Description: DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast
Study NCT02087163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Movement Enhancement Technique
Description: Conventional Orthodontic treatment
Study NCT02087163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clear Aligner
Description: Orthodontic treatment with Clear Aligner
Study NCT02232893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daikenchuto (TU-100)
Description: Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
Study NCT02232893 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 3 days before surgery and for 28 days after surgery.
Study NCT02468765 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological and emotional evaluation with monitoring
Description: Recognition tasks of emotional facial expressions with electroencephalogram, electrodermal activity measure and heart rate measure, questionnaires and neuropsychological tests
Study NCT04325750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TECAR Therapy
Description: The intervention will be performed with the T-Care TECAR® therapy machine at the latent trigger points of both gastrocnemius. The professional will apply the therapy with the generator that emits radio frequency signals of 0.5 MHz at a variable power with a maximum of 300W. The frequency to be used will be 500MHz with an intensity of 40% and with direct current.
Study NCT04325750 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: simulated TECAR Therapy (machine off)
Study NCT03182868 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAS Goggle
Description: PAS goggle is a self-contained stimulus and sensing device that is designed to deliver the visual stimuli currently delivered via light projected on a wall while simultaneously recording the movement of the eyes. Each vestibular testing session last about 15 minutes.
Study NCT02523976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT02523976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT02523976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin
Study NCT00576069 — intervention group
Intervention type: DRUG
Intervention: budesonide/formoterol
Description: 2 inhalations 2X/daily in treated arm/group. No placebo group
Study NCT00576069 — intervention group
Intervention type: DRUG
Intervention: fluticasone/salmeterol
Description: fluticasone 100ug/salmeterol 50ug, 1 inhalation bid noplacebo fluticasone 250ug/salmeterol 50ug, 1 inhalations bid no placebo Spiriva handihaler daily or respihaler 2 inhalations daily no placebo group
Study NCT00576069 — intervention group
Intervention type: DRUG
Intervention: mometasone/formoterol
Description: 200/5 mcg two puffs bid 100/5 mcg two puffs bid Breo Ellipta once daily Spiriva capsule handihaler once daily or Spiriva respihaler 2 in~no placebo group
Study NCT00576069 — intervention group
Intervention type: DRUG
Intervention: Prednisone
Description: 0-15 mg daily as needed
Study NCT05984953 — intervention group
Intervention type: DRUG
Intervention: statin
Description: 40 mg of rosuvastatin daily for 8-12 weeks
Study NCT05984953 — intervention group
Intervention type: DRUG
Intervention: evolocumab
Description: 140 mg evolocumab every 2 weeks (26 weeks)
Study NCT04514848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSTI Multiplex HIV-1/2 Syphilis AB test
Description: For the detection of antibodies to syphilis and HIV
Study NCT04514848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiplo Rapid TP/HIV test
Description: For the detection of antibodies to syphilis and HIV
Study NCT02363946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC-AAT Injection
Description: RNA interference-based, liver-targeted therapeutic
Study NCT03468387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suprapubic cystostomy
Description: Percutaneous cystostomy catheter will be inserted under sonographic guidance
Study NCT02511847 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Afatinib
Description: 1. Afatinib 40 mg per day for 14 days, then evaluation, every subject will go into the following phase no matter whether she had response or not~2. Afatinib 40 mg per day, day 1 to day 21, in combination with paclitaxel 80 mg/m² on days 1, 8, 15 in a 3-weekly course.
Study NCT02523976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Study NCT02523976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT02523976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Study NCT02523976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT02523976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study NCT02523976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone
Study NCT02523976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT02523976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Study NCT02523976 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Study NCT02298153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: atezolizumab: administered intravenously (IV) every three weeks (q3w)
Study NCT02298153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epacadostat
Description: epacadostat: Oral daily dosing
Study NCT03727919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exoskeleton-assisted gait training
Description: In the experimental groups, participants are provided with 1-hour sessions of gait training with robot assistance, 4 times per week for 4 weeks. Assistance is provided by the Ekso GT (Ekso Bionics, Richmond, CA, USA), an exoskeleton consisting of fitted metal braces that supports the legs, feet, and trunk of the patient. Powered motors drive knee and hip joints in the sagittal plane to assist during standing up and walking over level surfaces. Steps are initiated if an active weight-shift towards the stance leg is performed by the patient. The provided assistance in stance and swing is adaptable to the patient's ability and can be adjusted for each leg separately.
Study NCT03542942 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: treatment with EXIT-target volume
Description: exclusion of the unaffected part of the uterus out of the treatment field
Study NCT03158038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza Vaccine
Description: A single dose of monovalent influenza vaccine \[10\^7.0 +/- 0.5 FFU of each of 1 ca, att, ts 6:2 reassortant influenza strain\] will be administered as intranasal spray on Day 1.
Study NCT03158038 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo matching with monovalent influenza vaccine will be administered as intranasal spray on Day 1.
Study NCT01644071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cipralex
Description: one time 10 mg, tablet
Study NCT02187198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Study NCT01136057 — intervention group
Intervention type: BIOLOGICAL
Intervention: Collection of Anti-Influenza A Immune Plasma
Study NCT00572936 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Latanoprost
Description: prostaglandin
Study NCT00572936 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dorzolamide
Description: carbonic anhydrase inhibitor
Study NCT00572936 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Timolol
Description: beta blocker
Study NCT00771342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: 1% gaseous nitric oxide, delivered for 40 minutes daily for 3 consecutive days
Study NCT00771342 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen
Description: Nitrogen gas, delivered topically for 40 minutes daily for 3 consecutive days
Study NCT00703586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: ARM A:~Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses:~* 150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor~* 600 mg orally BID when coadministered with efavirenz or nevirapine~ARM B:~Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:~* Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc.~* Addition of an alternate FDA approved NRTI \[such as zidovudine (AZT) or didanosine (ddi)\] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.~* Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc.
Study NCT00703586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: ARM A:~Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses:~* 150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor~* 600 mg orally BID when coadministered with efavirenz or nevirapine~ARM B:~Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:~* Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc.~* Addition of an alternate FDA approved NRTI \[such as zidovudine (AZT) or didanosine (ddi)\] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.~* Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc.
Study NCT02363946 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9 % normal saline
Study NCT02363946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.
Study NCT02363946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.
Study NCT06069596 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Natalis Obstetric Lubrican Gel
Description: The obstetric lubricant gel was applied to the vaginal canal with a special applicator at the beginning of the active phase of the labor. The gel used in the study was highly viscose and isotonic with a slight acid pH of 6.0 - 6.7 and contained hydroxyethylcellulose, propylene glycol, glycerin. The gel box contained a sterile syringe (15 ml) and a flexible applicator.
Study NCT03552471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03552471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mirvetuximab Soravtansine
Description: Given IV
Study NCT03552471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study NCT03552471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib Camsylate
Description: Given PO
Study NCT04340206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: face-to-face support and Chatbot online support group
Description: Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to support adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program. In addition, they meet and get support from their human coach (i.e., psychology student) twice in the face-to-face meetings.
Study NCT04340206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: only chat-robot online support group
Description: Behavioral: Structured web- and mobile-based intervention with Youth Compass plus program to adolescents' psychological flexibility, well-being, and subsequently support successful transition to upper secondary education. The Youth Compass plus is a five-week online program aiming to enhance adolescents' psychological flexibility by guiding adolescents in exploring their values and setting goals and changing behaviors according to their goals (week 1), and learning acceptance, defusion and mindfulness skills (weeks 2-3) and integrating these skills into their personal and social life (weeks 4-5). The participants in this condition receive weekly online support and feedback from the eCoach built within the program.
Study NCT04340206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group, no intervention
Description: Behavioral: No intervention
Study NCT00303524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: Injection 3.6 mg monthly
Study NCT00303524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: injection 10.8 mg every 3 months
Study NCT00113568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid tablets (XP12B)
Description: Two 650 mg tranexamic acid tablets (XP12B) taken 3 times daily (3900 mg/Day) for a maximum of 5 days during monthly menstruation
Study NCT01161316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX-6 + cetuximab until disease progression or early withdrawal.
Description: Treatment regimen:~mFOLFOX-6, day 1, every two weeks; OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations.
Study NCT01161316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.
Description: Treatment regimen.~mFOLFOX-6. day 1 every two weeks. OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours~Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations.
Study NCT01655030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine monohydrate
Study NCT01655030 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02341417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Cinacalcet was provided as 5 mg capsules for sprinkling or as 30 mg film-coated tablets for swallowing. The protocol-specified doses were: 1, 2.5, 5, 7.5, 10, 15, 30, 60, 90, 120, and 180 mg.
Study NCT01588379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girls and mothers Afro-centric dance program
Description: African-American girls and their mom's will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
Study NCT01588379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girls, alone
Description: African-American girls (without their mom's) will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
Study NCT01588379 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Newsletter
Description: Both girls and the mothers will receive weekly newsletter containing various health information.
Study NCT01556087 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distress Tolerance
Description: 7 individual sessions aimed at increasing distress tolerance skills
Study NCT01556087 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education
Description: 7 individual sessions with didactic health education information
Study NCT02039596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet